{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T05:36:35Z","timestamp":1791351395637,"version":"4.3.1"},"reference-count":61,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,6,21]],"date-time":"2024-06-21T00:00:00Z","timestamp":1718928000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100002565","name":"ADDF","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002565","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000049","name":"NIA","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neurobiology of Disease"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1016\/j.nbd.2024.106575","type":"journal-article","created":{"date-parts":[[2024,6,22]],"date-time":"2024-06-22T11:58:59Z","timestamp":1719057539000},"page":"106575","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"special_numbering":"C","title":["An interim exploratory proteomics biomarker analysis of a phase 2 clinical trial to assess the impact of CT1812 in Alzheimer's disease"],"prefix":"10.1016","volume":"199","author":[{"given":"B.N.","family":"Lizama","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.A.","family":"North","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Pandey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Williams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Duong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Cho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Di Caro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Ping","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Blennow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Zetterberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Lah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.I.","family":"Levey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Grundman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.O.","family":"Caggiano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.T.","family":"Seyfried","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.E.","family":"Hamby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"12","key":"10.1016\/j.nbd.2024.106575_bb0005","doi-asserted-by":"crossref","first-page":"2555","DOI":"10.1038\/s41591-022-02074-w","article-title":"Differential roles of A\u03b242\/40, p-tau231 and p-tau217 for Alzheimer\u2019s trial selection and disease monitoring","volume":"28","author":"Ashton","year":"2022","journal-title":"Nat. Med."},{"issue":"1","key":"10.1016\/j.nbd.2024.106575_bb0010","article-title":"Biomarker potential of brain-secreted extracellular vesicles in blood in Alzheimer\u2019s disease","volume":"12","author":"Badhwar","year":"2020","journal-title":"Alzheimer\u2019s Dement."},{"issue":"13","key":"10.1016\/j.nbd.2024.106575_bb0015","doi-asserted-by":"crossref","first-page":"6958","DOI":"10.1074\/jbc.M115.689539","article-title":"Clusterin binds to A\u03b21-42 oligomers with high affinity and interferes with peptide aggregation by inhibiting primary and secondary nucleation","volume":"291","author":"Beeg","year":"2016","journal-title":"J. Biol. Chem."},{"issue":"7","key":"10.1016\/j.nbd.2024.106575_bb0020","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1002\/acn3.51402","article-title":"Multi-cohort profiling reveals elevated CSF levels of brain-enriched proteins in Alzheimer\u2019s disease","volume":"8","author":"Bergstr\u00f6m","year":"2021","journal-title":"Ann. Clin. Transl. Neurol."},{"issue":"1","key":"10.1016\/j.nbd.2024.106575_bb0025","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/0169-328X(95)00097-C","article-title":"Association of apolipoprotein E genotype with brain levels of apolipoprotein E and apolipoprotein J (clusterin) in Alzheimer disease","volume":"33","author":"Bertrand","year":"1995","journal-title":"Brain Res. Mol. Brain Res."},{"issue":"6","key":"10.1016\/j.nbd.2024.106575_bb0030","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1111\/joim.12816","article-title":"Biomarkers for Alzheimer\u2019s disease: current status and prospects for the future","volume":"284","author":"Blennow","year":"2018","journal-title":"J. Intern. Med."},{"key":"10.1016\/j.nbd.2024.106575_bb0035","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/bs.pmbts.2019.07.006","article-title":"Fluid biomarker-based molecular phenotyping of Alzheimer\u2019s disease patients in research and clinical settings","volume":"168","author":"Blennow","year":"2019","journal-title":"Prog. Mol. Biol. Transl. Sci."},{"issue":"18","key":"10.1016\/j.nbd.2024.106575_bb0040","doi-asserted-by":"crossref","first-page":"2534","DOI":"10.1097\/00001756-199412000-00032","article-title":"Cerebrospinal fluid apolipoprotein E is reduced in Alzheimer\u2019s disease","volume":"5","author":"Blennow","year":"1994","journal-title":"Neuroreport"},{"key":"10.1016\/j.nbd.2024.106575_bb0045","doi-asserted-by":"crossref","DOI":"10.14283\/jpad.2022.30","article-title":"Two randomized phase 3 studies of Aducanumab in early Alzheimer\u2019s Disease","author":"Budd Haeberlein","year":"2022","journal-title":"J. Prev Alzheimers Dis."},{"key":"10.1016\/j.nbd.2024.106575_bb0050","author":"Cavazzioni"},{"issue":"10","key":"10.1016\/j.nbd.2024.106575_bb0055","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1097\/00005072-199710000-00004","article-title":"Dendritic translocation of RC3\/neurogranin mRNA in normal aging, Alzheimer disease and fronto-temporal dementia","volume":"56","author":"Chang","year":"1997","journal-title":"J. Neuropathol. Exp. Neurol."},{"issue":"1","key":"10.1016\/j.nbd.2024.106575_bb0060","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/s13195-020-00588-4","article-title":"The clinical promise of biomarkers of synapse damage or loss in Alzheimer\u2019s disease","volume":"12","author":"Colom-Cadena","year":"2020","journal-title":"Alzheimers Res. Ther."},{"key":"10.1016\/j.nbd.2024.106575_bb0065","article-title":"Transmembrane protein 97 is a potential synaptic amyloid beta receptor in human Alzheimer\u2019s disease","volume":"2023","author":"Colom-Cadena","year":"2023","journal-title":"Acta Neuropathol"},{"issue":"2","key":"10.1016\/j.nbd.2024.106575_bb0070","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0031039","article-title":"Rare variants in APP, PSEN1 and PSEN2 increase risk for AD in late-onset Alzheimer\u2019s disease families","volume":"7","author":"Cruchaga","year":"2012","journal-title":"PLoS ONE"},{"issue":"2","key":"10.1016\/j.nbd.2024.106575_bb0075","article-title":"Alzheimer\u2019s disease drug development pipeline: 2023","volume":"9","author":"Cummings","year":"2023","journal-title":"Alzheimer\u2019s Dement."},{"key":"10.1016\/j.nbd.2024.106575_bb0080","doi-asserted-by":"crossref","first-page":"164","DOI":"10.3389\/fnins.2019.00164","article-title":"Clusterin in Alzheimer\u2019s Disease: mechanisms, genetics, and lessons from other pathologies","volume":"13","author":"Foster","year":"2019","journal-title":"Front. Neurosci."},{"issue":"2","key":"10.1016\/j.nbd.2024.106575_bb0085","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1515\/cclm-2021-0651","article-title":"Validation of the LUMIPULSE automated immunoassay for the measurement of core AD biomarkers in cerebrospinal fluid","volume":"60","author":"Gobom","year":"2022","journal-title":"Clin. Chem. Lab. Med."},{"issue":"12","key":"10.1016\/j.nbd.2024.106575_bb0090","doi-asserted-by":"crossref","first-page":"4141","DOI":"10.1096\/fj.201600816R","article-title":"Decreased synaptic proteins in neuronal exosomes of frontotemporal dementia and Alzheimer\u2019s disease","volume":"30","author":"Goetzl","year":"2016","journal-title":"FASEB J."},{"issue":"1","key":"10.1016\/j.nbd.2024.106575_bb0095","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.trci.2018.11.001","article-title":"A phase 1 clinical trial of the sigma-2 receptor complex allosteric antagonist CT1812, a novel therapeutic candidate for Alzheimer\u2019s disease","volume":"5","author":"Grundman","year":"2019","journal-title":"Alzheimer\u2019s Dement."},{"key":"10.1016\/j.nbd.2024.106575_bb0100","series-title":"Global Analysis of the Heparin-Enriched Plasma Proteome Captures Matrisome-Associated Proteins in Alzheimer\u2019s Disease","author":"Guo","year":"2023"},{"issue":"10","key":"10.1016\/j.nbd.2024.106575_bb0105","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1038\/ng.440","article-title":"Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer\u2019s disease","volume":"41","author":"Harold","year":"2009","journal-title":"Nat. Genet."},{"issue":"43","key":"10.1016\/j.nbd.2024.106575_bb0110","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.aaz9360","article-title":"Integrated proteomics reveals brain-based cerebrospinal fluid biomarkers in asymptomatic and symptomatic Alzheimer\u2019s disease","volume":"6","author":"Higginbotham","year":"2020","journal-title":"Sci. Adv."},{"issue":"2","key":"10.1016\/j.nbd.2024.106575_bb0115","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1021\/pr501076j","article-title":"An integrated workflow for multiplex CSF proteomics and peptidomics-identification of candidate cerebrospinal fluid biomarkers of Alzheimer\u2019s disease","volume":"14","author":"H\u00f6ltt\u00e4","year":"2015","journal-title":"J. Proteome Res."},{"issue":"5","key":"10.1016\/j.nbd.2024.106575_bb0120","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1080\/19336918.2015.1019996","article-title":"The cross-talk of LDL-cholesterol with cell motility: insights from the Niemann pick type C1 mutation and altered integrin trafficking","volume":"9","author":"Hoque","year":"2015","journal-title":"Cell Adhes. Migr."},{"issue":"11","key":"10.1016\/j.nbd.2024.106575_bb0125","article-title":"Alzheimer\u2019s therapeutics targeting amyloid Beta 1\u201342 oligomers I: abeta 42 oligomer binding to specific neuronal receptors is displaced by drug candidates that improve cognitive deficits","volume":"9","author":"Izzo","year":"2014","journal-title":"PLoS ONE"},{"issue":"11","key":"10.1016\/j.nbd.2024.106575_bb0130","article-title":"Alzheimer\u2019s therapeutics targeting amyloid beta 1-42 oligomers II: Sigma-2\/PGRMC1 receptors mediate Abeta 42 oligomer binding and synaptotoxicity","volume":"9","author":"Izzo","year":"2014","journal-title":"PLoS ONE"},{"issue":"8","key":"10.1016\/j.nbd.2024.106575_bb0135","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1002\/alz.12302","article-title":"Preclinical and clinical biomarker studies of CT1812: a novel approach to Alzheimer\u2019s disease modification","volume":"17","author":"Izzo","year":"2021","journal-title":"Alzheimer\u2019s Dement."},{"issue":"12","key":"10.1016\/j.nbd.2024.106575_bb0140","doi-asserted-by":"crossref","first-page":"4768","DOI":"10.1073\/pnas.1216206110","article-title":"Genome-wide scan of healthy human connectome discovers SPON1 gene variant influencing dementia severity","volume":"110","author":"Jahanshad","year":"2013","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"2","key":"10.1016\/j.nbd.2024.106575_bb0145","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1038\/s41593-021-00999-y","article-title":"Large-scale deep multi-layer analysis of Alzheimer\u2019s disease brain reveals strong proteomic disease-related changes not observed at the RNA level","volume":"25","author":"Johnson","year":"2022","journal-title":"Nat. Neurosci."},{"issue":"3","key":"10.1016\/j.nbd.2024.106575_bb0150","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.neuron.2009.06.026","article-title":"The role of apolipoprotein E in Alzheimer\u2019s Disease","volume":"63","author":"Kim","year":"2009","journal-title":"Neuron"},{"issue":"3","key":"10.1016\/j.nbd.2024.106575_bb0155","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1038\/s41588-019-0358-2","article-title":"Genetic meta-analysis of diagnosed Alzheimer\u2019s disease identifies new risk loci and implicates A\u03b2, tau, immunity and lipid processing","volume":"51","author":"Kunkle","year":"2019","journal-title":"Nat. Genet."},{"issue":"1","key":"10.1016\/j.nbd.2024.106575_bb0160","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/s40035-023-00358-w","article-title":"A phase 1b randomized clinical trial of CT1812 to measure A\u03b2 oligomer displacement in Alzheimer\u2019s disease using an indwelling CSF catheter","volume":"12","author":"LaBarbera","year":"2023","journal-title":"Transl. Neurodegener."},{"issue":"10","key":"10.1016\/j.nbd.2024.106575_bb0165","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1038\/ng.439","article-title":"Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer\u2019s disease","volume":"41","author":"Lambert","year":"2009","journal-title":"Nat. Genet."},{"key":"10.1016\/j.nbd.2024.106575_bb0170","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.ceb.2015.01.003","article-title":"Neurofilament assembly and function during neuronal development","volume":"32","author":"Laser-Azogui","year":"2015","journal-title":"Curr. Opin. Cell Biol."},{"issue":"1","key":"10.1016\/j.nbd.2024.106575_bb0175","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/1742-2094-5-37","article-title":"Neuro-inflammation induced by lipopolysaccharide causes cognitive impairment through enhancement of beta-amyloid generation","volume":"5","author":"Lee","year":"2008","journal-title":"J. Neuroinflammation"},{"issue":"6","key":"10.1016\/j.nbd.2024.106575_bb0180","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.1093\/brain\/awab452","article-title":"A phase II study repurposing atomoxetine for neuroprotection in mild cognitive impairment","volume":"145","author":"Levey","year":"2022","journal-title":"Brain"},{"issue":"7","key":"10.1016\/j.nbd.2024.106575_bb0185","doi-asserted-by":"crossref","first-page":"6251","DOI":"10.3390\/ijms24076251","article-title":"Sigma-2 receptors\u2014from basic biology to therapeutic target: a focus on age-related degenerative diseases","volume":"24","author":"Lizama","year":"2023","journal-title":"Int. J. Mol. Sci."},{"issue":"54","key":"10.1016\/j.nbd.2024.106575_bb0190","doi-asserted-by":"crossref","first-page":"93219","DOI":"10.18632\/oncotarget.21479","article-title":"Association of HLA-DRB1 polymorphism with Alzheimer\u2019s disease: a replication and meta-analysis","volume":"8","author":"Lu","year":"2017","journal-title":"Oncotarget"},{"issue":"25","key":"10.1016\/j.nbd.2024.106575_bb0195","doi-asserted-by":"crossref","first-page":"6333","DOI":"10.1523\/JNEUROSCI.0829-08.2008","article-title":"Complement C3 deficiency leads to accelerated amyloid plaque deposition and neurodegeneration and modulation of the microglia\/macrophage phenotype in amyloid precursor protein transgenic mice","volume":"28","author":"Maier","year":"2008","journal-title":"J. Neurosci."},{"issue":"1","key":"10.1016\/j.nbd.2024.106575_bb0200","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1186\/s13024-023-00638-z","article-title":"Quantitative proteomics of cerebrospinal fluid from African Americans and Caucasians reveals shared and divergent changes in Alzheimer\u2019s disease","volume":"18","author":"Modeste","year":"2023","journal-title":"Mol. Neurodegener."},{"issue":"1","key":"10.1016\/j.nbd.2024.106575_bb0205","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1038\/nsmb.2191","article-title":"The extracellular chaperone clusterin sequesters oligomeric forms of the amyloid-\u03b2(1-40) peptide","volume":"19","author":"Narayan","year":"2011","journal-title":"Nat. Struct. Mol. Biol."},{"issue":"10","key":"10.1016\/j.nbd.2024.106575_bb0210","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1002\/glia.21004","article-title":"Astrocytic a beta 1-42 uptake is determined by a beta-aggregation state and the presence of amyloid-associated proteins","volume":"58","author":"Nielsen","year":"2010","journal-title":"Glia"},{"issue":"12","key":"10.1016\/j.nbd.2024.106575_bb0215","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1038\/nrn.2016.138","article-title":"Integrins in synapse regulation","volume":"17","author":"Park","year":"2016","journal-title":"Nat. Rev. Neurosci."},{"issue":"21","key":"10.1016\/j.nbd.2024.106575_bb0220","doi-asserted-by":"crossref","first-page":"3480","DOI":"10.1002\/1873-3468.13193","article-title":"Models of synaptotagmin-1 to trigger Ca2+ -dependent vesicle fusion","volume":"592","author":"Park","year":"2018","journal-title":"FEBS Lett."},{"issue":"26","key":"10.1016\/j.nbd.2024.106575_bb0225","doi-asserted-by":"crossref","first-page":"11062","DOI":"10.1073\/pnas.0609621104","article-title":"Cellular prion protein regulates beta-secretase cleavage of the Alzheimer\u2019s amyloid precursor protein","volume":"104","author":"Parkin","year":"2007","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"9","key":"10.1016\/j.nbd.2024.106575_bb0230","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1038\/nm.3302","article-title":"PDK1 decreases TACE-mediated \u03b1-secretase activity and promotes disease progression in prion and Alzheimer\u2019s diseases","volume":"19","author":"Pietri","year":"2013","journal-title":"Nat. Med."},{"issue":"1","key":"10.1016\/j.nbd.2024.106575_bb0235","doi-asserted-by":"crossref","DOI":"10.1038\/sdata.2018.36","article-title":"Global quantitative analysis of the human brain proteome in Alzheimer\u2019s and Parkinson\u2019s Disease","volume":"5","author":"Ping","year":"2018","journal-title":"Sci. Data"},{"issue":"Pt A","key":"10.1016\/j.nbd.2024.106575_bb0240","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.neuropharm.2013.09.018","article-title":"A role for tau at the synapse in Alzheimer\u2019s disease pathogenesis","volume":"76","author":"Pooler","year":"2014","journal-title":"Neuropharmacology"},{"issue":"12","key":"10.1016\/j.nbd.2024.106575_bb0245","doi-asserted-by":"crossref","first-page":"7689","DOI":"10.1074\/jbc.274.12.7689","article-title":"Interactions between neurogranin and calmodulin in vivo","volume":"274","author":"Prichard","year":"1999","journal-title":"J. Biol. Chem."},{"issue":"1","key":"10.1016\/j.nbd.2024.106575_bb0250","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-018-35430-3","article-title":"Sigma-2 receptor\/TMEM97 and PGRMC-1 increase the rate of internalization of LDL by LDL receptor through the formation of a ternary complex","volume":"8","author":"Riad","year":"2018","journal-title":"Sci. Rep."},{"issue":"9","key":"10.1016\/j.nbd.2024.106575_bb0255","doi-asserted-by":"crossref","first-page":"3803","DOI":"10.1007\/s12035-020-01988-1","article-title":"The sigma-2 receptor\/TMEM97, PGRMC1, and LDL receptor complex are responsible for the cellular uptake of A\u03b242 and its protein aggregates","volume":"57","author":"Riad","year":"2020","journal-title":"Mol. Neurobiol."},{"key":"10.1016\/j.nbd.2024.106575_bb0260","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.neurobiolaging.2019.10.025","article-title":"Intracellular and secreted forms of clusterin are elevated early in Alzheimer\u2019s disease and associate with both A\u03b2 and tau pathology","volume":"89","author":"Shepherd","year":"2020","journal-title":"Neurobiol. Aging"},{"issue":"1","key":"10.1016\/j.nbd.2024.106575_bb0265","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.jalz.2013.01.008","article-title":"Genome-wide association study of the rate of cognitive decline in Alzheimer\u2019s disease","volume":"10","author":"Sherva","year":"2014","journal-title":"Alzheimers Dement."},{"issue":"D1","key":"10.1016\/j.nbd.2024.106575_bb0270","doi-asserted-by":"crossref","first-page":"D638","DOI":"10.1093\/nar\/gkac1000","article-title":"The STRING database in 2023: protein\u2013protein association networks and functional enrichment analyses for any sequenced genome of interest","volume":"51","author":"Szklarczyk","year":"2023","journal-title":"Nucleic Acids Res."},{"issue":"1","key":"10.1016\/j.nbd.2024.106575_bb0275","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1038\/s43587-023-00550-7","article-title":"Cerebrospinal fluid proteomics in patients with Alzheimer\u2019s disease reveals five molecular subtypes with distinct genetic risk profiles","volume":"4","author":"Tijms","year":"2024","journal-title":"Nat. Aging"},{"issue":"1","key":"10.1016\/j.nbd.2024.106575_bb0280","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa2212948","article-title":"Lecanemab in early Alzheimer\u2019s disease","volume":"388","author":"van Dyck","year":"2023","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.nbd.2024.106575_bb0285","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/s13195-024-01382-2","article-title":"A pilot study to evaluate the effect of CT1812 treatment on synaptic density and other biomarkers in Alzheimer\u2019s disease","volume":"16","author":"van Dyck","year":"2024","journal-title":"Alzheimers Res. Ther."},{"issue":"1","key":"10.1016\/j.nbd.2024.106575_bb0290","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1038\/s41597-023-02158-3","article-title":"Quantitative mass spectrometry analysis of cerebrospinal fluid protein biomarkers in Alzheimer\u2019s Disease","volume":"10","author":"Watson","year":"2023","journal-title":"Sci. Data"},{"issue":"1","key":"10.1016\/j.nbd.2024.106575_bb0295","first-page":"63","article-title":"Prediction of conversion from mild cognitive impairment to dementia with neuronally derived blood exosome protein profile","volume":"3","author":"Winston","year":"2016","journal-title":"Alzheimer\u2019s Dement."},{"issue":"3","key":"10.1016\/j.nbd.2024.106575_bb0300","doi-asserted-by":"crossref","first-page":"971","DOI":"10.3233\/JAD-180302","article-title":"Growth hormone-releasing hormone modulation of neuronal exosome biomarkers in mild cognitive impairment","volume":"66","author":"Winston","year":"2018","journal-title":"J. Alzheimers Dis."},{"issue":"1","key":"10.1016\/j.nbd.2024.106575_bb0305","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1001\/jamaneurol.2015.3037","article-title":"Association of cerebrospinal fluid neurofilament light concentration with Alzheimer disease progression","volume":"73","author":"Zetterberg","year":"2016","journal-title":"JAMA Neurol."}],"container-title":["Neurobiology of Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S096999612400175X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S096999612400175X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,3]],"date-time":"2025-02-03T07:28:03Z","timestamp":1738567683000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S096999612400175X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9]]},"references-count":61,"alternative-id":["S096999612400175X"],"URL":"https:\/\/doi.org\/10.1016\/j.nbd.2024.106575","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2024.02.16.578765","asserted-by":"object"}]},"ISSN":["0969-9961"],"issn-type":[{"value":"0969-9961","type":"print"}],"subject":[],"published":{"date-parts":[[2024,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"An interim exploratory proteomics biomarker analysis of a phase 2 clinical trial to assess the impact of CT1812 in Alzheimer's disease","name":"articletitle","label":"Article Title"},{"value":"Neurobiology of Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.nbd.2024.106575","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"106575"}}